Intranasal delivery of growth differentiation factor 5 to the central nervous system

Drug Delivery

Volumn 19, Issue 3, 2012, Pages 149-154

  Hanson, Leah R ^a   Fine, Jared M ^a   Hoekman, John D ^a   Nguyen, Thuhien M ^a   Burns, Rachel B ^a   Martinez, Paula M ^a   Pohl, Jens ^b   Frey II, William H ^a,c  

^a REGIONS HOSPITAL   (United States)

^b Biopharm GmbH   (Germany)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

dopamine; GDF5; lipid microemulsion; Parkinson's disease; solubility

Indexed keywords

ACETIC ACID; GROWTH DIFFERENTIATION FACTOR 5;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONCENTRATION (PARAMETERS); DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MESENCEPHALON; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; DRUG DELIVERY SYSTEMS; GROWTH DIFFERENTIATION FACTOR 5; HUMANS; MALE; MESENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84858662115     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.657720     Document Type: Article

References (31)

1. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. (2004). Intranasal insulin improves memory in humans. Psychoneuroendocrinology, 29, 1326-1334. (Pubitemid 39024358)
2. Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL, Born J, Kern W. (2007a). Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology, 32, 239-243. (Pubitemid 44967803)
3. Benedict C, Hallschmid M, Schultes B, Born J, Kern W. (2007b). Intranasal insulin to improve memory function in humans. Neuroendocrinology, 86, 136-142. (Pubitemid 47494214)
4. Charlton ST, Whetstone J, Fayinka ST, Read KD, Illum L, Davis SS. (2008). Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model. Pharm Res, 25, 1531-1543.
5. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. (2007). Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm, 337, 1-24. (Pubitemid 46756063)
6. Dhanda DS, Frey WHI, Leopold D, Kompella UB. (2005). Approaches for Drug Deposition in the Human Olfactory Epithelium. Drug Delivery, 5, 64-72.
7. Dhuria SV, Hanson LR, Frey WH 2nd. (2009). Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci, 98, 2501-2515.
8. Dhuria SV, Hanson LR, Frey WH 2nd. (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci, 99, 1654-1673.
9. Fandel TM, Bella AJ, Lin G, Tantiwongse K, Lin CS, Pohl J, Lue TF. (2008). Intracavernous growth differentiation factor-5 therapy enhances the recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med, 5, 1866-1875.
10. Fawcett JR, Chen X, Rahman YE, Frey WH. (1999). Previously reported nerve growth factor levels are underestimated due to an incomplete release from receptors and interaction with standard curve media. Brain Res, 842, 206-210. (Pubitemid 29447868)
11. Frey WH, 2ND, INVENTOR. Method of Administering Neurologic Agents to the Brain. US patent 5 624 898. April 29, 1997.
12. Fukui H, Koike T, Saheki A, Sonoke S, Seki J. (2003). A novel delivery system for amphotericin B with lipid nano-sphere (LNS). Int J Pharm, 265, 37-45. (Pubitemid 37176944)
13. Hanson LR, Martinez PM, Taheri S, Kamsheh L, Mignot E, Frey WHI. (2004). Intranasal Administration of Hypocretin 1 (Orexin A) Bypasses the Blood-Brain Barrier & Targets the Brain: A New Strategy for the Treatment of Narcolepsy. Drug Delivery Technology, 4, 81-86.
14. Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, Marti DL, Hoekman JD, Matthews RB, Frey WH 2nd, Panter SS. (2009). Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther, 330, 679-686.
15. Hurley FM, Costello DJ, Sullivan AM. (2004). Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson's disease. Exp Neurol, 185, 281-289. (Pubitemid 38084854)
16. Migliore MM, Vyas TK, Campbell RB, Amiji MM, Waszczak BL. (2010). Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci, 99, 1745-1761.
17. Nickel J, Kotzsch A, Sebald W, Mueller TD. (2005). A single residue of GDF-5 defines binding specificity to BMP receptor IB. J Mol Biol, 349, 933-947. (Pubitemid 40779617)
18. Nonaka N, Farr SA, Kageyama H, Shioda S, Banks WA. (2008). Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J Pharmacol Exp Ther, 325, 513-519. (Pubitemid 351574811)
19. Porecha S, shah T, Jogani V, Naik S, Misra A. (2009). Microemulsion based intranasal delivery system for treatment of insomnia. Drug Deliv, 16, 128-134.
20. Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S. (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging, 27, 451-458. (Pubitemid 43185331)
21. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH 2nd, Craft S. (2008a). Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis, 13, 323-331. (Pubitemid 352039034)
22. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. (2008b). Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology, 70, 440-448.
23. Seki J, Sonoke S, Saheki A, Fukui H, Sasaki H, Mayumi T. (2004). A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int J Pharm, 273, 75-83. (Pubitemid 38317042)
24. Sieber C, Plöger F, Schwappacher R, Bechtold R, Hanke M, Kawai S, Muraki Y, Katsuura M, Kimura M, Rechtman MM, Henis YI, Pohl J, Knaus P. (2006). Monomeric and dimeric GDF-5 show equal type I receptor binding and oligomerization capability and have the same biological activity. Biol Chem, 387, 451-460.
25. Storm EE, Huynh TV, Copeland NG, Jenkins NA, Kingsley DM, Lee SJ. (1994). Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily. Nature, 368, 639-643. (Pubitemid 24153388)
26. Sullivan AM, O'Keeffe GW. (2005). The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment. J Anat, 207, 219-226. (Pubitemid 41300997)
27. Sullivan AM, Opacka-Juffry J, Pohl J, Blunt SB. (1999). Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration. Brain Res, 818, 176-179. (Pubitemid 29227300)
28. Takuwa Y, Ohue Y, Takuwa N, Yamashita K. (1989). Endothelin-1 activates phospholipase C and mobilizes Ca2+ from extra-and intracellular pools in osteoblastic cells. Am J Physiol, 257, E797-E803.
29. Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH 2nd. (2008). Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience, 152, 785-797.
30. Vyas TK, Shahiwala A, Marathe S, Misra A. (2005). Intranasal drug delivery for brain targeting. Curr Drug Deliv, 2, 165-175. (Pubitemid 40488626)
31. Yang JP, Liu HJ, Cheng SM, Wang ZL, Cheng X, Yu HX, Liu XF. (2009). Direct transport of VEGF from the nasal cavity to brain. Neurosci Lett, 449, 108-111.